3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
3
Ovarian Neoplasms
3
Thyroid Neoplasms
2
Sarcoma
2
Parathyroid Neoplasms
2
Otorhinolaryngologic Neoplasms
2
Osteosarcoma
2
Mixed Tumor, Mesodermal
2
Mesothelioma, Cystic
2
Mesothelioma
2
Lung Neoplasms
2
Liposarcoma
2
Leiomyosarcoma
2
Kidney Neoplasms
2
Hemangiosarcoma
2
Head and Neck Neoplasms
2
Fibrosarcoma
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Chondrosarcoma
2
Carcinoma, Small Cell
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Adenosarcoma
2
Tracheal Neoplasms
1
Solitary Pulmonary Nodule
1
Pulmonary Sclerosing Hemangioma
1
Prostatic Neoplasms
1
Phyllodes Tumor
1
Pancoast Syndrome
1
Interventions
pembrolizumab
93
Gemcitabine
56
Nivolumab
50
Cisplatin
39
atezolizumab
37
Carboplatin
30
avelumab
29
enfortumab vedotin
27
Docetaxel
23
Magnetic Resonance Spectroscopy
19
Mitomycin
17
Ipilimumab
17
Paclitaxel
16
Specimen Handling
14
durvalumab
11
toripalimab
10
sacituzumab govitecan
10
Pemetrexed
10
cabozantinib
9
Taxes
8
vinflunine
7
Injections
7
Cyclophosphamide
7
tislelizumab
6
Bevacizumab
6
pemigatinib
5
fludarabine
5
disitamab vedotin
5
Standard of Care
5
Radiosurgery
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
belinostat
×
Genitourinary
×
Clear all
NCT05154994
2026-05-07
RESOLVE
University of Utah
Phase 1
Active not recruiting
9 enrolled